{"id":"https://openalex.org/W4361920596","doi":"https://doi.org/10.1158/1078-0432.22462154","title":"Supplementary Material from Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia","display_name":"Supplementary Material from Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361920596","doi":"https://doi.org/10.1158/1078-0432.22462154"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22462154","doi":"https://doi.org/10.1158/1078-0432.22462154","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22462154","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.22462154","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101651850","display_name":"Na Shen","orcid":"https://orcid.org/0009-0002-7519-923X","observed_orcids":["https://orcid.org/0009-0002-7519-923X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Na Shen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100665489","display_name":"Fei Yan","orcid":"https://orcid.org/0000-0002-6904-1498","observed_orcids":["https://orcid.org/0000-0002-6904-1498"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fei Yan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104033675","display_name":"Jiuxia Pang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jiuxia Pang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102016731","display_name":"Na Zhao","orcid":"https://orcid.org/0000-0003-1892-567X","observed_orcids":["https://orcid.org/0000-0003-1892-567X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Na Zhao","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002643270","display_name":"Naseema Gangat","orcid":"https://orcid.org/0000-0002-9104-6172","observed_orcids":["https://orcid.org/0000-0002-9104-6172"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Naseema Gangat","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052947767","display_name":"Lai\u2010Chu Wu","orcid":"https://orcid.org/0000-0002-1348-269X","observed_orcids":["https://orcid.org/0000-0002-1348-269X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Laichu Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051769949","display_name":"Ann M. Bode","orcid":"https://orcid.org/0000-0002-7432-082X","observed_orcids":["https://orcid.org/0000-0002-7432-082X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ann M. Bode","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008422091","display_name":"Aref Al\u2010Kali","orcid":"https://orcid.org/0000-0002-0824-3715","observed_orcids":["https://orcid.org/0000-0002-0824-3715"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aref Al-Kali","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085360755","display_name":"Mark Robert Litzow","orcid":"https://orcid.org/0000-0002-9816-6302","observed_orcids":["https://orcid.org/0000-0002-9816-6302"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark R. Litzow","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5100726820","display_name":"Shujun Liu","orcid":"https://orcid.org/0000-0002-2605-8089","observed_orcids":["https://orcid.org/0000-0002-2605-8089"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shujun Liu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10269","display_name":"Epigenetics and DNA Methylation","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9829999804496765},{"id":"https://openalex.org/keywords/receptor-tyrosine-kinases","display_name":"receptor tyrosine kinase","score":0.9290000200271606},{"id":"https://openalex.org/keywords/dna-methylation","display_name":"DNA methylation","score":0.8730000257492065},{"id":"https://openalex.org/keywords/dnmt1","display_name":"DNMT1","score":0.9810000061988831},{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":0.9800000190734863},{"id":"https://openalex.org/keywords/kit","display_name":"KIT","score":0.75},{"id":"https://openalex.org/keywords/flt3","display_name":"FLT3","score":0.9909999966621399},{"id":"https://openalex.org/keywords/sp1","display_name":"Sp1","score":0.9449999928474426},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.8180000185966492},{"id":"https://openalex.org/keywords/decitabine","display_name":"decitabine","score":0.8069999814033508},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.7549999952316284},{"id":"https://openalex.org/keywords/cyclin-dependent-kinase-inhibitors","display_name":"cyclin-dependent kinase inhibitors","score":0.8629999756813049},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.7870000004768372},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.753000020980835},{"id":"https://openalex.org/keywords/epigenetic-reprogramming","display_name":"epigenetic reprogramming","score":0.6570000052452087}],"concepts":[{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.9058632254600525},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6481262445449829},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6454684734344482},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.6339014768600464},{"id":"https://openalex.org/C175211621","wikidata":"https://www.wikidata.org/wiki/Q14907998","display_name":"DNMT1","level":5,"score":0.5362493395805359},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5012931823730469},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.497419148683548},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.46033889055252075},{"id":"https://openalex.org/C33288867","wikidata":"https://www.wikidata.org/wiki/Q518328","display_name":"Methylation","level":3,"score":0.45148593187332153},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.41404157876968384},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3446303904056549},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.20759347081184387},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.19371157884597778},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.14499470591545105},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.14052778482437134},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.13757780194282532},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.07885727286338806},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.07056471705436707}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22462154","doi":"https://doi.org/10.1158/1078-0432.22462154","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22462154","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22462154.v1","doi":"https://doi.org/10.1158/1078-0432.22462154.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22462154.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Material_from_Inactivation_of_Receptor_Tyrosine_Kinases_Reverts_Aberrant_DNA_Methylation_in_Acute_Myeloid_Leukemia/22462154/1/files/39913445.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22462154","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Material_from_Inactivation_of_Receptor_Tyrosine_Kinases_Reverts_Aberrant_DNA_Methylation_in_Acute_Myeloid_Leukemia/22462154","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22462154","doi":"https://doi.org/10.1158/1078-0432.22462154","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22462154","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.766700029373169}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361920596.pdf","grobid_xml":"https://content.openalex.org/works/W4361920596.grobid-xml"},"referenced_works_count":11,"referenced_works":["https://openalex.org/W1813888483","https://openalex.org/W1904308459","https://openalex.org/W1967140970","https://openalex.org/W1971273349","https://openalex.org/W2022335352","https://openalex.org/W2042764921","https://openalex.org/W2062579284","https://openalex.org/W2168116239","https://openalex.org/W2338146212","https://openalex.org/W2530495093","https://openalex.org/W2554898019"],"related_works":["https://openalex.org/W2739363814","https://openalex.org/W4361945319","https://openalex.org/W2212324737","https://openalex.org/W1813888483","https://openalex.org/W2075407045","https://openalex.org/W3084291896","https://openalex.org/W1997874833","https://openalex.org/W6920287551","https://openalex.org/W2161932315","https://openalex.org/W2571049132"],"abstract_inverted_index":{"Supplementary":[0,5,20,31,46,58,74,83,96,107,121,133,145,165,183,195],"Methods,":[1],"Figures":[2],"and":[3,27,43,56,65,118,179],"References":[4],"Figure":[6,21,32,47,59,75,84,97,108,122,134,146,166,184],"1.":[7],"Tyrosine":[8],"kinases":[9],"are":[10],"positive":[11],"regulators":[12],"of":[13,105,155,169,189],"DNMT-dependent":[14],"DNA":[15,68,87,156,192],"methylation":[16,69,88,157],"in":[17,41,44,91,116,130,158,200],"leukemia":[18],"cells.":[19],"2.":[22],"Nilotinib":[23,61,124,148],"treatment":[24,62,125],"inhibits":[25],"KIT":[26],"FLT3":[28],"kinase":[29,81],"signaling.":[30],"3.":[33],"Treatment":[34],"with":[35],"RTK":[36,55,77],"inhibitors":[37,82],"decreases":[38],"DNMT1":[39],"expression":[40,178],"vitro":[42],"vivo.":[45],"4.":[48],"The":[49,186],"potential":[50],"biochemical":[51],"link":[52],"between":[53],"an":[54],"DNMT1.":[57],"5.":[60],"induces":[63,150],"global":[64],"gene":[66],"specific":[67],"through":[70,153],"the":[71,102,159,201],"Sp1-DNMT1":[72],"axis.":[73],"6.":[76],"dysfunction":[78],"reactivates":[79],"cyclin-dependent":[80],"7.":[85],"DNMT1-dependent":[86],"is":[89],"increased":[90],"cells":[92,141,173],"resistant":[93],"to":[94,111,114,142,174],"nilotinib.":[95,106],"8.":[98],"Sp1":[99],"overexpression":[100],"reduces":[101],"antileukemia":[103],"activity":[104],"9.":[109],"Exposure":[110,168],"nilotinib":[112,143,175],"leads":[113],"changes":[115,129],"pro-":[117],"anti-apoptotic":[119],"proteins.":[120],"10.":[123],"displays":[126],"no":[127],"obvious":[128],"cell":[131,151,163,181],"cycle.":[132],"11.":[135],"Velcade":[136],"or":[137],"decitabine":[138],"sensitizes":[139],"AML":[140,162,170],"treatment.":[144],"12.":[147],"exposure":[149],"apoptosis":[152],"modulation":[154],"C1498":[160],"mouse":[161],"line.":[164],"13.":[167],"patient":[171],"primary":[172],"suppresses":[176],"oncogene":[177],"promotes":[180],"apoptosis.":[182],"14.":[185],"anti-leukemia":[187],"activities":[188],"imatinib":[190],"involve":[191],"methylation-associated":[193],"pathways.":[194],"Table.":[196],"Primer/probe":[197],"sequences":[198],"used":[199],"experiments":[202]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2023-04-05T00:00:00"}